Biora Therapeutics, Inc. (BIOR) Tops Q2 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Biora Therapeutics, Inc. (BIOR) Tops Q2 EPS by 9c

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 15, 2022 4:06 PM EDT

Successfully completed PM-602 human study for its targeted therapeutics platform demonstrating
promising device performance in active ulcerative colitis patients

Successfully completed PM-611 human study for its targeted therapeutics platform in healthy volunteers
showing promising performance regardless of feeding schedule

Confirmed planned phase 1 IND filing in Q1 based on FDA feedback on PGN-600 program in ulcerative
colitis

Strengthened patent position for both targeted and systemic therapeutics platforms

Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM... More